BMC Cancer

OCT 24, 2026 · JOURNAL ARTICLE

Outcome-specific differences between randomized trials and real-world studies of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative advanced breast cancer: a meta-epidemiological analysis

BMC Cancer

Abstract Background Real-world evidence is increasingly interpreted alongside randomized clinical trial evidence in oncology, but reported outcomes may differ because of variation

OCT 23, 2026 · JOURNAL ARTICLE

Radiotherapy of multiple brain metastases using AGuIX nanoparticles: a prospective randomized phase II study protocol

BMC Cancer

Occurrence of multiple brain metastases is a critical evolution of many cancers with significant neurological and overall survival consequences, despite new-targeted therapy and st

OCT 23, 2026 · JOURNAL ARTICLE

Ultrasound-guided precision therapy for breast cancer: evidence mapping of targeted nanobubble-enhanced imaging, local drug delivery, and combination immunotherapy

BMC Cancer

Breast cancer precision therapy faces drug delivery and response prediction challenges. Ultrasound micro/nanobubble platforms integrate theranostic functions but lack consistent ev

OCT 23, 2026 · JOURNAL ARTICLE

Neoadjuvant immunochemotherapy and pathological response in locally advanced cervical cancer: a real-world bicenter cohort study

BMC Cancer

Neoadjuvant chemotherapy (NACT) followed by radical surgery remains an option for selected patients with locally advanced cervical cancer (LACC) in settings where access to definit

OCT 23, 2026 · JOURNAL ARTICLE

Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study

BMC Cancer

The optimal treatment after progression on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for EGFR -mutated non-small cell lung cancer (NSCLC) remains uncl

OCT 22, 2026 · JOURNAL ARTICLE

Intrinsic validity of molecular marker(s) detection on tissue tumor DNA to predict efficacy of 177Lutetium-PSMA-617 ([177Lu]Lu-PSMA-617) treatment for castration-resistant metastatic prostate cancer (PSMA-PRED): study protocol of a prospective multicentre clinical trial

BMC Cancer

Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and poor survival outcomes (5-year survival rate of approximately 30%). Radioligand therapy wi

OCT 22, 2026 · JOURNAL ARTICLE

Initial dose of fruquintinib and clinical outcomes in patients with refractory metastatic colorectal cancer: a multicenter real-world study

BMC Cancer

Fruquintinib is an established treatment for patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. However, treatment-related adverse even

OCT 22, 2026 · JOURNAL ARTICLE

Lung cancer in a low-smoking caribbean population: clinicopathological and molecular characteristics from Martinique (2020–2023)

BMC Cancer

Lung cancer epidemiology varies considerably across populations. Martinique, a French Caribbean territory with a predominantly Afro-Caribbean population and a daily smoking prevale